Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)

Critical Limb Ischemia Clinical Trial

Official title:
A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Due to Arteriosclerosis Obliterans (ASO) With a Single-arm Substudy to Assess the Safety and Potential Efficacy of CLBS12 in Patients With CLI Due to Buerger's Disease (BD)

Status Completed

Clinical Trial Summary

A prospective, open label, controlled, randomized, double arm, multi-center study to assess the efficacy and safety of CLBS12 in patients with critical limb ischemia (CLI) due to arteriosclerosis obliterans (ASO) with a single arm sub-study to assess the safety and potential efficacy of CLBS12 in patients with CLI due to Buerger's Disease (BD).

Clinical Trial Description

Main ASO Study: This study will compare safety and efficacy of intramuscular transplantation of autologous CD34+ cells (CLBS12) plus standard of care (SOC) pharmacotherapy (cell treatment arm) versus SOC pharmacotherapy alone (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids) (control arm) in subjects with CLI categorized as Rutherford score 4 or 5 due to ASO aged 20 to 85 years and with no endovascular or surgical revascularization options. Subjects assigned to the cell treatment arm will continue SOC pharmacotherapy and will also receive subcutaneous injections of GRAN® 5 ug/kg/day for 5 days and undergo apheresis on the last day of GRAN® administration. Then each subject in the cell treatment arm will receive intramuscular injections of autologous CD34+ cells. Subjects assigned to the control arm will continue to receive SOC pharmacotherapy alone with the possibility of receiving cell treatment via the rescue option. BD Substudy: A single arm substudy is included to assess the safety and efficacy of intramuscular transplantation of CLBS12 in patients (N=~5) with CLI categorized as 4 or 5 Rutherford score due to BD aged 20 to 85 years. Subjects who give informed consent will be screened for eligibility within 28 days before registration. Subjects will continue SOC pharmacotherapy and will also receive subcutaneous injections of GRAN® 5 µg/kg/day for 5 days (Pretreatment Days 1 5) to mobilize CD34+ cells into the peripheral blood and undergo apheresis on pretreatment Day 5 to collect CD34+ cells. The choice of pharmacotherapy will be made by the investigators. Each subject in a cell treatment arm will receive intramuscular injections of up to 1 × 10^6 autologous CD34+ cells/kg/limb. All subjects will be evaluated for efficacy and safety assessments during approximately 12 months. Efficacy assessments include CLI free status, AFS, PFS, ABI, TBI, SPP, TcPO2, ICD, VAS, and AQA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02501018
Study type	Interventional
Source	Lisata Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	November 1, 2017
Completion date	May 19, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03987061` - MOTIV Bioresorbable Scaffold in BTK Artery Disease	N/A
Recruiting	`NCT03668353` - Recombinant SeV-hFGF2/dF Injection for PAOD	Phase 1
Recruiting	`NCT04110964` - Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT	Phase 1
Not yet recruiting	`NCT03994666` - Cell Therapy in Critical Limb Ischemia	Phase 2
Recruiting	`NCT02389023` - Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery	N/A
Not yet recruiting	`NCT02498080` - Drug Eluting Balloons PTA in Infra-popliteal Arteries in Patients With Critical Limb Ischemia	N/A
Completed	`NCT02539940` - Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
Recruiting	`NCT02239419` - Evaluation of Carbothera in the Treatment of Foot Ulcers	N/A
Recruiting	`NCT01938872` - Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia	N/A
Active, not recruiting	`NCT01211925` - Distal Venous Arterialisation of Ischemic Limb	Phase 2/Phase 3
Completed	`NCT02454231` - Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA)	Phase 2/Phase 3
Completed	`NCT01758874` - Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia	Phase 2
Completed	`NCT02475200` - Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems
Recruiting	`NCT04583436` - Efficacy and Safety Comparison of the Open and Endovascular Surgical Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Below the Knee, TASC D in Patients With Critical Limb Ischemia	N/A
Completed	`NCT04071782` - Investigating the Safety and Efficacy of the Treatment With the Selution Sirolimus Coated Balloon in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb Ischemia From Singapore	N/A
Completed	`NCT03669458` - Feasibility Clinical Trial Using the SPUR System to Demonstrate Safety and Efficacy.	N/A
Not yet recruiting	`NCT06007469` - Pedal Acceleration Time (PAT) as a Measure of Foot Perfusion
Recruiting	`NCT04110327` - An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease
Completed	`NCT02260622` - Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia	Phase 2
Recruiting	`NCT02054416` - External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality	N/A